CDKN2A and cancer: Frequent deletions and mutations of CDKN2A (a negative regulator of cell cycle, also known as p16) in lung cancer were first observed in 1994 [52] and hypermethylation and silencing was subsequently observed to occur in substantial numbers of cancers carrying an intact gene [53].